On this page
Sun Pharma secures global ex-US, ex-China rights to PCSK9 cholesterol drug
Our read
Sun Pharma turns lerodalcibep into a selective ex-US specialty launch, but reimbursement and entrenched PCSK9 competition make the revenue ramp gradual rather than immediately transformative.
For operators
Sun Pharma gains a potential specialty-care growth lever in cholesterol management, but launch timing and revenue will depend on regulatory approvals across its licensed markets.
Watch
Regulatory filing and approval timelines for lerodalcibep in key ex-US, ex-China territories.
The report,
Sun Pharma secured exclusive rights to commercialise and manufacture lerodalcibep outside the US and China, targeting a $3.7 billion PCSK9 market. It will pursue regulatory approvals in territories where the cholesterol drug is not yet approved.
- Estimated PCSK9 cholesterol-treatment market
- $3.7 billion
Reported figures
From the report. Source details below
- once a month
Other figures
- 12 months ended Q2 2026
- 38%
- $2.9 billion
- $7 billion
Why it matters to operators
This licensing agreement demonstrates Sun Pharma’s strategy of using targeted partnerships to access differentiated global assets without acquiring full worldwide rights.
What to watch next
- Published clinical data, label language and any evidence of differentiation on LDL-C lowering, dosing frequency, safety or adherence.
- Commercial terms disclosed by either company, including upfront payments, milestones, royalties and supply responsibilities.
- Reimbursement decisions and treatment-positioning guidelines for PCSK9 therapies in major markets.
- Competitive pricing and access moves by Repatha, Praluent, Leqvio and emerging oral lipid-lowering treatments.
- Sun Pharma commentary on launch timing, specialty revenue contribution and cardiovascular sales-force investment.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Sequence regulatory submissions across major licensed markets, likely prioritizing India, Europe, Japan and other markets where Sun has commercial scale.
- Build a medical-affairs and payer-value narrative around LDL-C reduction, dosing convenience, adherence and use in high-risk cardiovascular patients.
- Prepare local manufacturing, cold-chain, pharmacovigilance and distribution capabilities ahead of approvals.
- Pursue formulary and reimbursement negotiations, potentially using differentiated pricing by market.
- Evaluate adjacent cardiovascular licensing, co-promotion or diagnostic partnerships to support specialist reach.
The counter-case
The case against this reading — not reported by the source.
The deal may be strategically narrower than the headline suggests: it excludes the US and China, while the remaining markets are fragmented, reimbursement-sensitive and expensive to launch in. Lerodalcibep still requires regulatory approvals, and even approval would not ensure uptake against entrenched PCSK9 rivals such as Repatha and Praluent, plus Novartis's inclisiran. Sun Pharma could face sizable medical-affairs, market-access and distribution investment before meaningful revenue, while undisclosed licensing economics may dilute returns. The cited $3.7 billion market opportunity is not necessarily addressable by Sun Pharma or indicative of near-term sales.